• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Editor's Pick

Dr. Marty Makary advances out of key committee in bid for FDA confirmation

by March 13, 2025
written by March 13, 2025

President Donald Trump’s nominee to lead the Food and Drug Administration (FDA), Dr. Marty Makary, passed a key committee vote 14-9 on Thursday morning, clearing the way for a full Senate vote on his nomination. 

If confirmed before the full Senate, Makary will work alongside the nominee for National Institute of Health (NIH) Director Dr. Jay Bhattacharya to achieve Secretary of Health and Human Services Robert F. Kennedy Jr.’s Make America Healthy Again agenda. 

The Senate Committee on Health, Education, Labor and Pensions(HELP) voted in favor of Makary’s confirmation following his committee hearing one week ago today. 

‘We now have a generational opportunity in American healthcare. President Trump and Secretary Kennedy’s focus on healthy foods has galvanized a grassroots movement in America. Childhood obesity is not a willpower problem, and the rise of early-onset Alzheimer’s is not a genetic cause. We should be, and we will, be addressing food as it impacts our health,’ Makary said last week. 

‘Thanks to the courage of President Trump and Secretary Kennedy, we now have a generational opportunity to usher in radical transparency to facilitate more cures, meaningful treatments and diagnostics at the FDA to help people take care of their own health,’ Makary added.

Makary was grilled by Democrats last week on vaccines, abortion, chronic illness and food safety. When repeatedly asked by Democratic senators on the committee whether he would revoke the approval process for Mifepristone, Makary said any decision on the abortion pill will come down to science. 

‘I have no preconceived plans on Mifepristone policy except to take a solid, hard look at the data and to meet with the professional career scientists who have reviewed the data at the FDA, and to build an expert coalition to review the ongoing data,’ he said. 

Makary, who advocated for natural immunity during the COVID-19 pandemic, flipped a question about vaccine processes around on Sen. Patty Murray, D-Wash., during his confirmation hearing, telling her to ask former President Joe Biden why he skipped a key step when it came to the COVID-19 booster. 

‘So, if you are confirmed, will you commit to immediately reschedule that FDA Vaccine Advisory Committee meeting to get the expert views?’ Sen. Patty Murray, D-Wash., asked Trump’s FDA pick. 

‘I would re-evaluate which topics deserve a convening of the advisory committee members on [Vaccines and Related Biological Products Advisory Committee] and which may not require a convening,’ Makary replied, adding that he was not a part of the decision. 

When asked again by Murray, he said: ‘Well, you can ask the Biden administration that chose not to convene the committee meeting for the COVID vaccine booster.’

He vowed during his committee hearing to lead his own Department of Government Efficiency (DOGE) investigations if confirmed. DOGE has terminated the employment of thousands of probationary HHS employees, including those at the FDA, since Trump took office. 

‘If confirmed, I will do my own independent assessment on personnel. I welcome input on efficiencies at the agency. At the same time, I want to make sure that the scientists and food inspectors and staff, central to the core mission of the agency, have all the resources they need to do their job well,’ Makary said last week. 

Makary has long been a critic of the FDA. He penned an opinion piece in 2021 that called for ‘fresh leadership at the FDA to change the culture at the agency and promote scientific advancement, not hinder it.’

Trump nominated Johns Hopkins School of Medicine professor, pancreatic surgeon and former Fox News medical contributor Dr. Marty Makary for FDA commissioner in November. 

‘I am very pleased to nominate Marty Makary MD, MPH, FACS, for FDA Commissioner,’ Trump said in a statement. ‘FDA has lost the trust of Americans, and has lost sight of its primary goal as a regulator. The Agency needs Dr. Marty Makary, a Highly Respected Johns Hopkins Surgical Oncologist and Health Policy Expert, to course-correct and refocus the Agency.’ 

Trump said that Makary will ‘work under the leadership of Robert F. Kennedy Jr. to, among other things, properly evaluate harmful chemicals poisoning our Nation’s food supply and drugs and biologics being given to our Nation’s youth, so that we can finally address the Childhood Chronic Disease Epidemic.’

Fox News Digital’s Julia Johnson contributed to this report.

This post appeared first on FOX NEWS
0 comment
0
FacebookTwitterPinterestEmail

previous post
FDA chief counsel who defended abortion pill access under Biden resigns two days into job
next post
Trump’s pick for NIH director clears committee, heads to full Senate vote

related articles

Kurilla warfare: Meet the general leading US military...

June 19, 2025

US Ambassador to Israel Mike Huckabee indicates US...

June 19, 2025

US troops in the Middle East could face...

June 19, 2025

Mystery flights from China to Iran raise questions...

June 19, 2025

Israel’s ‘resounding’ military campaign against Iran could be...

June 19, 2025

Trump to make Iran decision ‘within the next...

June 19, 2025

Two men convicted in Pennsylvania mayoral race election...

June 19, 2025

Flaring Iran nuclear crisis provides first major test...

June 19, 2025

Top Trump ally predicts Senate will blow past...

June 19, 2025

‘Instincts for restraint’: Senate divided over who gets...

June 19, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • RTX, GE Aerospace expect more than $1 billion tariff impact

    April 22, 2025
  • EURUSD and GBPUSD: GBPUSD under pressure to stay bullish

    September 30, 2024
  • Plug Power plummets 15% amid $200 million stock offering: Should you buy?

    July 19, 2024
  • Chair Jordan demands answers from dozens of major companies tied to shadowy ‘collusive’ ad group

    August 5, 2024
  • Incoming Trump administration given new blueprint on ways to weaken Iran: ‘unique opportunity’

    January 13, 2025

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 3

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 4

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (5,004)
  • Investing (634)
  • Stock (809)

Latest Posts

  • Supreme Court Chief Justice Roberts issues warning on ‘judicial independence’ weeks before Trump inauguration

    January 1, 2025
  • Secret Service Director Cheatle resigns after mounting pressure in wake of Trump assassination attempt

    July 23, 2024
  • Kash Patel’s nomination sparks enthusiasm, anxiety; future of the FBI appears uncertain

    December 1, 2024

Recent Posts

  • Incoming UK ambassador walks back comments on ‘danger’ of Trump: ‘Ill-judged and wrong’

    January 29, 2025
  • DOGE’s plans to offload government buildings supported by former GSA official

    March 16, 2025
  • Circuit court puts final nail in the coffin for Biden’s $500M student loan forgiveness plan

    February 18, 2025

Editor’s Pick

  • Mortgage rates plunge to the lowest level in over a year after weak employment report

    August 5, 2024
  • Trump says he’ll drop sanctions on Syria in move to normalize relations

    May 13, 2025
  • The dollar index is close to testing the September low

    September 16, 2024
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock